(Total Views: 657)
Posted On: 07/15/2024 3:26:43 PM
Post# of 154048
Very Interesting ohm, I asked Dr. AI to help me; please speak as you might to a young child or a Golden Retriever. It wasn't brains that got me here, I can assure you that.
It sounds like you're discussing a potential mechanism of action for Leronlimab in targeting RAS/RAS mutant signaling pathways. Leronlimab, primarily known as an antibody targeting CCR5, has shown promise in various therapeutic contexts, including cancer.
In this context, the proposed pathway—GTP > SRC > GRB2—suggests that Leronlimab might interfere with the downstream signaling typically activated by RAS proteins, which are crucial in cell proliferation and survival. By downregulating this pathway, Leronlimab could potentially inhibit the oncogenic effects of RAS mutations.
It sounds like you're discussing a potential mechanism of action for Leronlimab in targeting RAS/RAS mutant signaling pathways. Leronlimab, primarily known as an antibody targeting CCR5, has shown promise in various therapeutic contexts, including cancer.
In this context, the proposed pathway—GTP > SRC > GRB2—suggests that Leronlimab might interfere with the downstream signaling typically activated by RAS proteins, which are crucial in cell proliferation and survival. By downregulating this pathway, Leronlimab could potentially inhibit the oncogenic effects of RAS mutations.
(7)
(0)
